Anti-neural antibody response in patients with post-treatment Lyme disease symptoms versus those with myalgic encephalomyelitis/chronic fatigue syndrome.
Anti-neural antibody response in patients with post-treatment Lyme disease symptoms versus those with myalgic encephalomyelitis/chronic fatigue syndrome.
复制标题
治疗后莱姆病症状患者与肌痛性脑脊髓炎/慢性疲劳综合征患者的抗神经抗体反应。
DOI：
10.1016/j.bbi.2015.04.006
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Alaedini,Armin
中科院分区：
文献类型：
--
作者：
Ajamian,Mary;Cooperstock,Michael;Wormser,GaryP;Vernon,SuzanneD;Alaedini,Armin
治疗后莱姆病症状（PTLDS）和肌痛性脑脊髓炎/慢性疲劳综合征（ME/CFS）具有几个共同的临床特征，包括疲劳、肌肉骨骼疼痛和认知困难（Gaudino等人，1997年）。免疫机制已被怀疑在PTLDS和ME/CFS中发挥作用。然而，目前缺乏这两种疾病的生物标志物，这为更好地了解它们创造了障碍。在先前发表在BBI上的研究中，我们开发了半定量免疫印迹测定来比较一组PTLDS患者和对照中的抗体对神经抗原的反应性（Chandra等人，2010年）。先前描述了纳入/排除标准（Chandra等人，2010年）。我们发现PTLDS患者的IgG抗神经抗体反应性水平和频率显著增加（41/83; 49.4%）与既往接受过莱姆病治疗但无残留症状的患者相比（5/27; 18.5%）和从未患有莱姆病的健康对照（3/20; 15.0%）（两种比较p< 0.01）。PTLDS患者的抗神经抗体应答与伯氏疏螺旋体抗体的血清学阳性无关在一项新的分析中，我们使用相同的方法筛选了51名ME/CFS患者的血浆样本，（36名女性;平均[SD]年龄，51.2 [11.7]岁）和53名年龄和性别匹配的健康对照（40名女性;平均年龄，50.0 [13.6]岁），由SolveCFS BioBank提供（Irlbeck等人，2014年）。本研究获得了哥伦比亚大学医学中心机构审查委员会的批准。本研究中的ME/CFS和对照样本量提供了大于90%的功效，α< 0.05，以检测先前在PTLDS患者和相关对照中观察到的相同频率的抗体反应性（Chandra等人，2010年）。ME/CFS患者符合Fukuda或加拿大标准，
Post-treatment Lyme disease symptoms (PTLDS) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) have several clinical features in common, including fatigue, musculoskeletal pain, and cognitive difficulties (Gaudino et al., 1997). Immunologic mechanisms have been suspected to play a role in both PTLDS and ME/CFS. However, biomarkers for the two conditions are currently lacking, creating a barrier to better understand them. In a previous study published in BBI, we developed a semi-quantitative immunoblot assay to compare antibody reactivity to neural antigens in a group of PTLDS patients and controls (Chandra et al., 2010). Inclusion/exclusion criteria were previously described (Chandra et al., 2010). We found a significantly increased level and frequency of IgG anti-neural antibody reactivity in the PTLDS patients (41 of 83; 49.4%) both in comparison to patients who had been treated for Lyme disease previously but did not have residual symptoms (5 of 27; 18.5%) and to healthy controls who never had Lyme disease (3 of 20; 15.0%)(p< 0.01 for both comparisons). The anti-neural antibody response in the patients with PTLDS was independent of serologic positivity for antibodies to Borrelia burgdorferi (the etiologic agent of Lyme disease).Using the same methodology in a new analysis, we screened plasma samples from 51 ME/CFS patients (36 female; mean [SD] age, 51.2 [11.7] years) and 53 age-and gendermatched healthy controls (40 female; mean age, 50.0 [13.6] years), provided by the SolveCFS BioBank (Irlbeck et al., 2014). This study was approved by the Institutional Review Board of Columbia University Medical Center. The ME/CFS and control sample sizes in this study provided greater than 90% power, with α< 0.05, to detect the same frequencies of antibody reactivity previously observed in the PTLDS patients and associated controls (Chandra et al., 2010). ME/CFS patients met the Fukuda or the Canadian criteria for